Cyclizine Dose Rate Calculator
Calculate the appropriate cyclizine dosage based on patient weight, age, and administration route
Important Notice:
This calculator provides general guidance only and should not replace professional medical advice. Always consult a healthcare provider before administering cyclizine.
Recommended Cyclizine Dosage
Single Dose:
–
Daily Maximum:
–
Administration Route:
–
Frequency:
–
Comprehensive Guide to Calculating Cyclizine Dose Rates
Cyclizine is a first-generation antihistamine with anticholinergic properties primarily used to prevent and treat nausea, vomiting, and dizziness associated with motion sickness, vertigo, and post-operative recovery. Proper dosage calculation is crucial to ensure therapeutic efficacy while minimizing potential side effects.
Understanding Cyclizine Pharmacokinetics
Before calculating dosages, it’s essential to understand cyclizine’s pharmacological profile:
- Mechanism of Action: Cyclizine acts as an H1-receptor antagonist and muscarinic antagonist, affecting both the vestibular system and chemoreceptor trigger zone.
- Onset of Action: Oral administration typically shows effects within 30-60 minutes, while parenteral routes act within 15-30 minutes.
- Duration: The therapeutic effects last approximately 4-6 hours, influencing dosage frequency.
- Metabolism: Primarily hepatic metabolism with renal excretion of metabolites.
- Protein Binding: Approximately 75-80% protein-bound in plasma.
Standard Dosage Guidelines by Age Group
| Age Group | Oral Dose | IM/IV Dose | Maximum Daily Dose | Frequency |
|---|---|---|---|---|
| Adults (≥18 years) | 50 mg | 50 mg | 200 mg | Every 4-6 hours PRN |
| Adolescents (12-17 years) | 25-50 mg | 25 mg | 150 mg | Every 6-8 hours PRN |
| Children (6-11 years) | 12.5-25 mg | 12.5 mg | 75 mg | Every 8 hours PRN |
| Young Children (2-5 years) | 6.25-12.5 mg | Not typically recommended | 37.5 mg | Every 8-12 hours PRN |
Note: Dosages for children under 2 years are not typically recommended due to limited safety data and increased risk of anticholinergic effects.
Weight-Based Dosage Calculations
For more precise dosing, particularly in pediatric patients, weight-based calculations are preferred:
- Determine patient weight: Accurate measurement in kilograms is essential. For pediatric patients, use the most recent weight measurement.
- Select appropriate dose range:
- Oral: 0.5-1 mg/kg per dose
- IM/IV: 0.25-0.5 mg/kg per dose
- Calculate single dose:
- Minimum dose = weight (kg) × 0.5 mg/kg
- Maximum dose = weight (kg) × 1 mg/kg (oral) or 0.5 mg/kg (parenteral)
- Determine daily maximum:
- Adults: 200 mg/day
- Adolescents: 150 mg/day
- Children 6-11: 75 mg/day
- Children 2-5: 37.5 mg/day
- Adjust for frequency: Divide the daily maximum by the number of doses per day to ensure safety.
Special Considerations for Dosage Calculation
The following factors may require dosage adjustments:
- Renal Impairment: Cyclizine is primarily metabolized in the liver, but severe renal impairment (CrCl <30 mL/min) may require dose reduction or increased dosing intervals due to potential accumulation of metabolites.
- Hepatic Impairment: Patients with significant liver disease may require dose reduction as cyclizine undergoes extensive hepatic metabolism.
- Elderly Patients: Older adults (>65 years) may be more sensitive to anticholinergic effects. Consider starting at the lower end of the dosage range (e.g., 25 mg orally every 8 hours).
- Pregnancy: Cyclizine is classified as FDA Pregnancy Category B. While generally considered safe, use should be limited to situations where benefits outweigh potential risks, particularly in the first trimester.
- Drug Interactions: Cyclizine may potentiate the effects of other CNS depressants (e.g., opioids, benzodiazepines) and anticholinergic medications. Dosage adjustments may be necessary when used concomitantly.
Administration Routes and Bioavailability
| Route | Bioavailability | Onset of Action | Peak Effect | Duration | Common Uses |
|---|---|---|---|---|---|
| Oral (tablets) | ~100% | 30-60 minutes | 1-2 hours | 4-6 hours | Motion sickness prevention, general nausea/vomiting |
| Oral (liquid) | ~100% | 20-45 minutes | 1 hour | 4-6 hours | Pediatric dosing, patients with difficulty swallowing |
| Intramuscular (IM) | ~100% | 15-30 minutes | 30-60 minutes | 4-6 hours | Post-operative nausea, when oral route unavailable |
| Intravenous (IV) | ~100% | 5-15 minutes | 15-30 minutes | 4-6 hours | Severe nausea/vomiting, peri-operative setting |
The choice of administration route depends on several factors:
- Patient condition: Ability to tolerate oral medications, presence of vomiting
- Urgency: IV route provides the fastest onset for acute symptoms
- Setting: Hospital vs. outpatient environments
- Patient preference: Some patients may prefer oral over injectable routes
- Duration of therapy: Oral routes are more practical for extended treatment
Clinical Applications and Dosage Examples
Cyclizine’s dosage varies based on the specific clinical indication:
- Motion Sickness Prevention:
- Adults: 50 mg orally 30 minutes before travel, may repeat every 4-6 hours (max 200 mg/day)
- Children 6-12 years: 12.5-25 mg orally before travel, may repeat every 6-8 hours (max 75 mg/day)
- Post-Operative Nausea and Vomiting (PONV):
- Adults: 50 mg IM or IV at the end of surgery, may repeat every 6 hours (max 200 mg/day)
- Adolescents: 25 mg IM or IV, may repeat every 8 hours (max 150 mg/day)
- Vertigo Management:
- Adults: 50 mg orally three times daily (max 200 mg/day)
- Elderly: 25 mg orally two to three times daily (max 150 mg/day)
- Chemotherapy-Induced Nausea:
- Adults: 50 mg orally every 6-8 hours as needed (max 200 mg/day)
- Note: Cyclizine is typically used as adjunct therapy with more potent antiemetics
Monitoring and Adverse Effects
Proper monitoring is essential when administering cyclizine:
- Therapeutic Response: Assess reduction in nausea/vomiting symptoms, improvement in vertigo symptoms, or prevention of motion sickness.
- Adverse Effects: Common side effects include:
- Drowsiness or sedation (most common)
- Dry mouth
- Blurred vision
- Constipation
- Urinary retention
- Dizziness or confusion (particularly in elderly)
- Serious Reactions: Rare but potential serious effects include:
- Severe anticholinergic toxicity (agitation, hallucinations, tachycardia, hyperthermia)
- Hypotension (particularly with IV administration)
- Extrapyramidal symptoms (with high doses)
- Laboratory Monitoring: Generally not required for short-term use. For prolonged therapy (>1 week), consider:
- Renal function tests (if pre-existing impairment)
- Liver function tests (if pre-existing hepatic disease)
- Electrolytes (if significant vomiting was present)
If adverse effects occur, consider:
- Dose reduction
- Increasing the dosing interval
- Switching to an alternative antiemetic
- Supportive measures (e.g., fluids for dry mouth, stool softeners for constipation)
Comparative Efficacy with Other Antiemetics
Cyclizine’s efficacy should be considered in the context of alternative antiemetic medications:
| Medication | Mechanism | Onset | Duration | Common Uses | Advantages | Disadvantages |
|---|---|---|---|---|---|---|
| Cyclizine | H1 antagonist, anticholinergic | 30-60 min (oral) | 4-6 hours | Motion sickness, PONV, vertigo | Effective for vestibular causes, minimal sedation at low doses | Anticholinergic side effects, shorter duration |
| Ondansetron | 5-HT3 antagonist | 30 min (oral), 5 min (IV) | 8-12 hours | Chemotherapy, PONV, radiation | Broad spectrum, longer duration, fewer anticholinergic effects | More expensive, potential QT prolongation |
| Metoclopramide | D2 antagonist, 5-HT4 agonist | 30-60 min (oral), 1-3 min (IV) | 1-2 hours | Gastroparesis, chemotherapy, PONV | Prokinetic effects, central and peripheral action | Extrapyramidal effects, sedation |
| Promethazine | H1 antagonist, D2 antagonist | 20-60 min | 4-6 hours | Nausea/vomiting, motion sickness | Strong antiemetic effects, sedating | Significant sedation, anticholinergic effects |
| Dimenhydrinate | H1 antagonist | 30-60 min | 4-6 hours | Motion sickness, vertigo | OTC availability, effective for vestibular causes | Significant sedation, anticholinergic effects |
Selection among these agents depends on:
- The underlying cause of nausea/vomiting (vestibular vs. chemical vs. gastrointestinal)
- Patient-specific factors (age, comorbidities, concurrent medications)
- Desired sedative effects (cyclizine and promethazine are more sedating)
- Route of administration availability
- Cost considerations (cyclizine is generally more affordable than ondansetron)
Evidence-Based Recommendations
Several clinical guidelines provide evidence-based recommendations for cyclizine use:
- American Society of Health-System Pharmacists (ASHP):
- Recommends cyclizine as a first-line agent for vestibular-related nausea and motion sickness
- Suggests 50 mg IM/IV for PONV in adults, with consideration for lower doses in elderly patients
- Emphasizes the importance of weight-based dosing in pediatric populations
- National Institute for Health and Care Excellence (NICE):
- Includes cyclizine in their guidelines for managing nausea and vomiting in palliative care
- Recommends starting doses at the lower end of the range for frail or elderly patients
- Advises regular review of continued need for antiemetic therapy
- American Geriatrics Society (AGS):
- Cautions about increased sensitivity to anticholinergic effects in older adults
- Recommends cyclizine as a second-line agent after non-anticholinergic options in geriatric patients
- Suggests maximum daily dose of 100 mg for patients over 75 years
- Pediatric Society Recommendations:
- Emphasizes weight-based dosing for children
- Recommends against use in children under 2 years due to limited safety data
- Suggests liquid formulations for precise pediatric dosing
For the most current guidelines, healthcare professionals should consult:
- American Society of Health-System Pharmacists (ASHP)
- National Institute for Health and Care Excellence (NICE)
- American Geriatrics Society (AGS)
Practical Tips for Healthcare Providers
When prescribing or administering cyclizine, consider the following practical tips:
- Dose Timing: For motion sickness prevention, administer 30-60 minutes before travel. For PONV, administer at the end of surgery.
- Patient Education:
- Advise patients about potential drowsiness and to avoid operating machinery
- Recommend increased fluid intake to counteract dry mouth
- Instruct on proper storage (protect from light, store at room temperature)
- Dose Adjustments:
- For elderly patients, start with half the adult dose and titrate as needed
- For patients with renal or hepatic impairment, consider extended dosing intervals
- Monitoring Parameters:
- Assess for therapeutic response (reduction in nausea/vomiting)
- Monitor for anticholinergic side effects (dry mouth, urinary retention, confusion)
- Evaluate for signs of oversedation
- Alternative Forms:
- For patients with difficulty swallowing, consider liquid formulations or suppositories (where available)
- For pediatric patients, liquid formulations allow for more precise dosing
- Combination Therapy:
- For refractory nausea/vomiting, cyclizine may be combined with other antiemetics from different classes (e.g., ondansetron for chemotherapy-induced nausea)
- Be cautious of additive sedative effects when combining with other CNS depressants
Case Studies in Cyclizine Dosing
Examining real-world cases can help illustrate proper dosing strategies:
- Case 1: Motion Sickness in an Adult
- Patient: 35-year-old male, 80 kg, no significant medical history
- Indication: Prevention of motion sickness during a 6-hour boat trip
- Dosing:
- Initial dose: 50 mg orally 1 hour before departure
- Maintenance: 25 mg every 6 hours as needed (max 200 mg/day)
- Outcome: Effective prevention of motion sickness with minimal drowsiness
- Case 2: Post-Operative Nausea in a Child
- Patient: 8-year-old female, 25 kg, undergoing tonsillectomy
- Indication: Prevention of post-operative nausea and vomiting
- Dosing:
- Single dose: 12.5 mg IV at the end of surgery
- Maintenance: 12.5 mg orally every 8 hours PRN (max 37.5 mg/day)
- Outcome: No post-operative vomiting, minimal side effects
- Case 3: Vertigo in an Elderly Patient
- Patient: 78-year-old female, 60 kg, history of hypertension and mild cognitive impairment
- Indication: Symptomatic relief of vertigo associated with benign paroxysmal positional vertigo
- Dosing:
- Initial dose: 25 mg orally daily
- Titrated to 25 mg three times daily based on response and tolerance
- Outcome: Improved vertigo symptoms with careful monitoring for cognitive side effects
- Case 4: Chemotherapy-Induced Nausea
- Patient: 50-year-old male, 70 kg, receiving moderately emetogenic chemotherapy
- Indication: Adjunct therapy for chemotherapy-induced nausea
- Dosing:
- 50 mg orally 30 minutes before chemotherapy
- 25 mg every 6 hours PRN for breakthrough nausea (max 200 mg/day)
- Outcome: Reduced nausea episodes when used in combination with ondansetron
Common Dosage Calculation Errors and How to Avoid Them
Avoid these frequent mistakes in cyclizine dosing:
- Incorrect Weight Conversion:
- Error: Using pounds instead of kilograms in calculations
- Prevention: Always confirm weight is in kilograms; convert if necessary (1 kg ≈ 2.2 lb)
- Exceeding Maximum Daily Doses:
- Error: Administering doses too frequently, leading to cumulative daily doses above recommendations
- Prevention: Clearly document administration times and calculate 24-hour totals
- Inappropriate Route Selection:
- Error: Using IM route when oral would be sufficient, or vice versa
- Prevention: Assess patient’s ability to tolerate oral medications and urgency of symptom relief
- Ignoring Age-Specific Guidelines:
- Error: Using adult doses for pediatric patients or vice versa
- Prevention: Always verify age-specific dosing ranges before administration
- Overlooking Drug Interactions:
- Error: Not adjusting dose when used with other anticholinergic or sedating medications
- Prevention: Review complete medication profile and consider dose reductions when combining with interacting drugs
- Inadequate Monitoring:
- Error: Failing to assess for anticholinergic side effects, particularly in elderly patients
- Prevention: Implement regular monitoring for dry mouth, urinary retention, and cognitive changes
- Incorrect Dose Rounding:
- Error: Rounding doses inappropriately, especially for pediatric patients
- Prevention: Use liquid formulations when precise dosing is required; round to the nearest measurable dose
Future Directions in Cyclizine Research
Ongoing and future research may influence cyclizine dosing practices:
- Pharmacogenetic Studies: Research into how genetic variations affect cyclizine metabolism and response may lead to more personalized dosing regimens.
- Alternative Formulations: Development of extended-release formulations could improve compliance and reduce dosing frequency.
- Pediatric Pharmacokinetics: Additional studies in pediatric populations may refine weight-based dosing recommendations.
- Combination Therapies: Research into optimal combinations with other antiemetics for specific indications (e.g., chemotherapy) may emerge.
- Safety in Special Populations: Further studies in pregnant women, patients with severe organ impairment, and elderly populations may provide more precise dosing guidance.
- Alternative Routes: Investigation into transdermal or sublingual formulations could expand administration options.
Medical Disclaimer:
This calculator and guide are for informational purposes only and do not constitute medical advice. Cyclizine dosing should always be determined by a qualified healthcare professional based on individual patient assessment. The authors and publishers are not responsible for any adverse effects or consequences resulting from the use of this information.
Always consult current, authoritative medical sources and product labeling for the most up-to-date dosing recommendations. Local prescribing guidelines and institutional protocols may vary and should be followed.